^
Association details:
| Biomarker: | TP53 mutation |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | VE-821 (ATR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Inhibition of ATR Overcomes Chemotherapy Resistance in p53 Deficient Myeloma Cells
Published date:
11/06/2019
Excerpt:
By contrast, ATR inhibitor VE-821 (2.5mM) was efficient in both types of HMCLs (mean of death in TP53wt was 45% and 28% in TP53abn HMCLs, p=0.6)….Preliminary results of combos in 6 consecutive primary samples with MM or plasma cell leukemia (3 TP53wt and 3 TP53abn) demonstrated efficacy.
DOI:
https://doi.org/10.1182/blood-2019-122547
